Circulating Tumor Cell Market Research, Key Players, Analysis And Forecast 2027: Grand View Research Inc.
The global circulating
tumor cell market size is expected
to reach around USD 23.9 billion by 2027
at a CAGR of 13.2% over the forecast
period, according to a new report by Grand View Research, Inc. The growth in
cancer-related spending for the introduction of companion diagnostics and
targeted therapies has driven the circulating tumor cell (CTC) market over the
past years. Research organizations are engaged in endeavors aimed at developing
circulating tumor cells based tests to improve cancer diagnosis in terms of
efficiency and speed.
Biopharmaceutical innovators are at the
forefront of the human response to the coronavirus pandemic. A significant
number of major biotech firms are in the midst of a race to investigate the
Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the
speed of response to SARS/MERs etc, the biotech entities are investigating
SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are
being put into the R&D. With multiple candidates in trial, the public and
private sectors are anticipated to work in unison for the foreseeable period,
until a vaccine is developed for Covid-19. The report will account for Covid19
as a key market contributor.
Furthermore, the growing demand for
minimally invasive diagnostic procedures is anticipated to propel investments
by key stakeholders in this area. Circulating tumor cell based liquid biopsy
tests lead to limited trauma and enable rapid recovery owing to their
non-invasive nature. Moreover, it enables minimal invasive screening of tumors
before opting for complex surgical procedures, such as radiotherapy,
chemotherapy, and surgical removal of tumors, thus positively impacting the
adoption.
To Request Sample Copy of this report, click the link:
The limited applicability of these
cells in rare cancers has hampered the revenue growth up to a certain extent.
For instance, there is a negligible evidence for the characterization of
circulating tumor cells for sarcoma. Conversely, several methods are being
investigated for isolation of these cells, such as methods based on epithelial
antigen-targeted antibodies, which are anticipated to help overcome these challenges
in the coming years.
Further key findings from the report suggest:
·
CTC detection and enrichment
methods accounted for the largest revenue share owing to the presence of wide
availability of products for CTC enrichment and isolation
·
Moreover, high penetration in
terms of usage of products offered under this segment has driven the segment
share
·
Growing application of
nanomaterials in cancer management is anticipated to drive revenue for direct
detection methods in the coming years
·
Devices and systems dominated
the revenue share in 2020 over its counterpart segments including kits and
reagents and blood collection tubes
·
Presence of high-throughput
automated systems coupled with the availability of a substantial number of
systems to carry out detection of tumor cells has contributed to large revenue
share
·
CTC analysis has major
applications in research settings, including investigational research, drug
developments, and biomarker studies. This has resulted in a segment’s large
revenue share
·
Currently, whole blood
specimens are the key source of CTCs, thus accounting for the largest share in 2020
·
Low use of bone marrow-derived
cells in clinical settings has contributed to a smaller revenue share of this
segment
·
Other sources include CSF,
spinal fluids, urine, and pleural effusion
·
Easy availability of biological
specimens, such as urine, is likely to accelerate adoption under this segment
·
The CTC market is fragmented in
nature with the presence of well-established players, along with medium to
small-sized players
·
Some players operating in the
space are QIAGEN; Greiner Bio One International GmbH; Menarini Silicon
Biosystems; Sysmex Corporation; Bio-Techne Corporation; and Biocept, Inc.
Several
tumor markers that have been introduced in recent years can be used with
companion diagnostics to monitor or diagnose a variety of cancers. High
adoption of companion diagnostics in monitoring tumor eradication
characteristics of cytotoxic drugs is among the few factors propelling the
demand in the market for CTCs. Key stakeholders are constantly engaged in
endeavors aimed at developing circulating tumor cells based tests, which can
prove helpful in the cancer diagnosis.
Concerns related to the reliability
and consistency of isolation as well as the relationship between quantitation
of this biomarker and cancer prognosis are limiting factors affecting the
clinical utility of this biomarker. Although there is a wide availability of
several benchtop instruments for analysis and delineating circulating tumor
cells from other blood cells, it is difficult to characterize these cells due
to substantial phenotypes exhibited by these cells.
Have a Query? Ask
our experts:
Furthermore, this biomarker has long
been a subject of academic research, but the difficulty of centralizing the
know-how and technologies has obscured the path to commercialization as many
universities and private companies have developed their own expertise. However,
recent years have seen a drive toward practical application, majorly due to a
wave of acquisitions by large players centralizing the technology and numerous
tie-ups with pharmaceutical companies to make progress toward forming a value
chain and accelerate market growth.
Grand View Research has segmented the
global circulating tumor cell market on the basis of technology, application,
product, specimen, and region:
CTC Technology Outlook (Revenue, USD Million, 2016 -
2027)
·
CTC Detection & Enrichment
Methods
o Immunocapture (Label-based)
o Positive Selection
o Negative Selection
o Size-based Separation (Label-free)
o Membrane-based
o Microfluidic-based
o Density-based Separation (Label-free)
o Combined Methods
·
CTC Direct Detection Methods
o SERS
o Microscopy
o Others
·
CTC Analysis
CTC Application Outlook (Revenue, USD Million, 2016 -
2027)
·
Clinical/Liquid Biopsy
o Risk Assessment
o Screening and Monitoring
·
Research
o Cancer Stem Cell & Tumorigenesis Research
o Drug/Therapy Development
CTC Product Outlook (Revenue, USD Million, 2016 - 2027)
·
Kits & Reagents
·
Blood Collection Tubes
·
Devices or Systems
CTC Specimen Outlook (Revenue, USD Million, 2016 - 2027)
·
Blood
·
Bone Marrow
·
Other Body Fluids
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment